NCT04978506View on ClinicalTrials.gov

A Study in Healthy Men to Test How Well Different Doses of BI 1569912 Are Tolerated

PHASE1CompletedINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

September 3, 2021

Primary Completion Date

July 4, 2024

Study Completion Date

July 4, 2024

Conditions
Healthy
Interventions
DRUG

BI 1569912

BI 1569912

DRUG

Placebo

Placebo

Trial Locations (1)

10117

Charité - Universitätsmedizin Berlin, Berlin

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT04978506 - A Study in Healthy Men to Test How Well Different Doses of BI 1569912 Are Tolerated | Biotech Hunter | Biotech Hunter